



# Verona Pharma

8 February 2017

## Result of General Meeting Consolidation of Share Capital

---

For further information please contact: Verona Pharma plc

### **Verona Pharma plc**

Jan-Anders Karlsson, CEO  
Tel: +44 (0)20 3283 4200  
info@veronapharma.com

### **N+1 Singer (Nominated Adviser and UK Broker)**

Aubrey Powell / James White  
Tel: +44 (0)20 7496 3000

### **FTI Consulting**

Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins  
Tel: +44 (0)20 3727 1000  
veronapharma@fticonsulting.com

### **ICR, Inc. (US Media and Investor enquiries)**

James Heins  
Tel: +1 203-682-8251  
James.Heins@icrinc.com

Stephanie Carrington  
Tel. +1 646-277-1282  
Stephanie.Carrington@icrinc.com

---

### **About Verona Pharma plc**

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo and has shown clinically meaningful and statistically significant improvements in lung function when added to two commonly used bronchodilators as compared to either bronchodilator administered as a single agent. RPL554 has also shown anti-inflammatory effects and been well tolerated in clinical trials. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma.

### **Forward Looking Statements**

This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the development of DPI and MDI formulations of RPL554 and the potential for these formulations to increase the market opportunity for the product, if approved.

These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.